Long-Term Follow-Up of the TRED-HF Trial: Implications for Therapy in Patients with Dilated Cardiomyopathy and Heart Failure Remission
European Journal of Heart Failure · 01.01.2025 · 27 (1) · 113-123
DOI: 10.1002/ejhf.3475 ↗Kurz gefasst
Klinische Studie (Phase IV) in der Zeitschrift European Journal of Heart Failure, online erschienen am 30.09.2024. Verfasst von Leanne Cheng und 18 weiteren Autor:innen. Beteiligte Einrichtung: National Heart & Lung Institute, Imperial College, London, UK. Hauptthemen laut MEDLINE: Cardiomyopathy, Dilated, Heart Failure, Stroke Volume, Ventricular Function, Left. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: British Heart Foundation, Wellcome Trust.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Aims
In TRED-HF, 40% of patients with recovered dilated cardiomyopathy (DCM) relapsed in the short term after therapy withdrawal. This follow-up investigates the longer-term effects of therapy withdrawal. Methods and results TRED-HF was a randomized trial investigating heart failure therapy withdrawal in patients with recovered DCM over 6 months. Those randomized to continue therapy subsequently withdrew treatment between 6 and 12 months. Participants were recommended to restart therapy post-trial and were followed until May 2023. Clinical outcomes are reported in a non-randomized fashion from enrolment and from the end of the trial. The primary outcome was relapse defined as ≥10% reduction in left ventricular ejection fraction to <50%, doubling in N-terminal pro-B-type natriuretic peptide to >400 ng/L, or clinical features of heart failure. From enrolment to the last follow-up (median 6 years, interquartile range 6–7), 33 of 51 patients (65%) relapsed. The 5-year relapse rate from enrolment was 61% (95% confidence interval [CI] 45–73) and from the end of the trial was 39% (95% CI 19–54). Of 20 patients who relapsed during the trial, nine had a recurrent relapse during follow-up. Thirteen relapsed for the first time after the trial; seven had restarted low intensity therapy, four had not restarted therapy and two did not have therapy withdrawn. The mean intensity of therapy was lower after the trial compared to enrolment (mean difference −6 [−8 to −4]; p < 0.001). One third of relapses during follow-up had identifiable triggers (arrhythmia [n = 4], pregnancy [n = 1], hypertension [n = 1], infection [n = 1]). Corrected atrial fibrillation was associated with reduced risk of relapse (hazard ratio 0.33, 95% CI 0.12–0.96; p = 0.042).
Conclusions
The risk of relapse in the 5 years following the TRED-HF trial remained high. Restarting lower doses of heart failure medications at the end of the trial, external triggers and disease progression are likely to have contributed to relapse.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- National Heart & Lung Institute, Imperial College, London, UK.
- Inherited Cardiovascular Conditions Care Group & Cardiovascular Magnetic Resonance Unit, Royal Brompton and Harefield Hospitals, part of Guy's and St Thomas NHS Foundation Trust, London, UK.
- London School of Hygiene and Tropical Medicine, London, UK.
- Inherited Cardiovascular Conditions Group, Guy's and St Thomas NHS Foundation Trust, London, UK.
- British Heart Foundation Centre of Research Excellent, School of Cardiovascular and Metabolic Medicine and Sciences, King's College London, London, UK.
- MRC Laboratory of Medical Sciences, Imperial College, London, UK.
ORCID-Profile: Leanne Cheng
Förderung
- British Heart Foundation
- Wellcome Trust
Zitieren
APA
Cheng, L., Hammersley, D., Ragavan, A., Javed, S., Mukhopadhyay, S., Gregson, J., Han, J., Khalique, Z., Lota, A., Pantazis, A., Baksi, A. J., Carr-White, G., de Marvao, A., Ware, J., Tayal, U., Pennell, D. J., Cleland, J. G. F., Prasad, S. K., & Halliday, B. P. (2025). Long-Term Follow-Up of the TRED-HF Trial: Implications for Therapy in Patients with Dilated Cardiomyopathy and Heart Failure Remission. European Journal of Heart Failure, 27(1), 113-123. https://doi.org/10.1002/ejhf.3475
Vancouver
Cheng L, Hammersley D, Ragavan A, Javed S, Mukhopadhyay S, Gregson J, et al. Long-Term Follow-Up of the TRED-HF Trial: Implications for Therapy in Patients with Dilated Cardiomyopathy and Heart Failure Remission. European Journal of Heart Failure. 2025;27(1):113-123. doi:10.1002/ejhf.3475
BibTeX
@article{Cheng2025,
author = {Cheng, Leanne and Hammersley, Daniel and Ragavan, Aaraby and Javed, Saad and Mukhopadhyay, Srinjay and Gregson, John and Han, Jennie and Khalique, Zohya and Lota, Amrit and Pantazis, Antonis and Baksi, A John and Carr-White, Gerald and de Marvao, Antonio and Ware, James and Tayal, Upasana and Pennell, Dudley J and Cleland, John G F and Prasad, Sanjay K and Halliday, Brian P},
title = {Long-Term Follow-Up of the TRED-HF Trial: Implications for Therapy in Patients with Dilated Cardiomyopathy and Heart Failure Remission},
journal = {European Journal of Heart Failure},
year = {2025},
volume = {27},
number = {1},
pages = {113--123},
doi = {10.1002/ejhf.3475}
}
EUVIMED